Novo Nordisk A/S $NVO Shares Bought by Ameriprise Financial Inc.

Key Points

• Ameriprise Financial Inc. increased its stake in Novo Nordisk A/S by 9.4%, acquiring 123,579 additional shares to hold a total of 1,442,295 shares valued at $100.2 million.
• Analysts gave Novo Nordisk A/S an average rating of "Hold", with three analysts rating it as a Buy and two as a Sell.
• The company announced a semi-annual dividend of $0.4119 per share, with a payout ratio of 22.53%, scheduled for payment on August 26th.

Ameriprise Financial Inc. lifted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 9.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,442,295 shares of the company's stock after purchasing an additional 123,579 shares during the period. Ameriprise Financial Inc.'s holdings in Novo Nordisk A/S were worth $100,172,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. CW Advisors LLC lifted its holdings in Novo Nordisk A/S by 259.1% during the first quarter. CW Advisors LLC now owns 64,914 shares of the company's stock worth $4,633,000 after buying an additional 46,835 shares during the period. Martin Investment Management LLC lifted its holdings in Novo Nordisk A/S by 2.4% during the first quarter. Martin Investment Management LLC now owns 288,983 shares of the company's stock worth $20,067,000 after buying an additional 6,820 shares during the period. Flow Traders U.S. LLC purchased a new stake in Novo Nordisk A/S during the first quarter worth $1,629,000. Osterweis Capital Management Inc. lifted its holdings in Novo Nordisk A/S by 0.5% during the first quarter. Osterweis Capital Management Inc. now owns 228,690 shares of the company's stock worth $15,880,000 after buying an additional 1,071 shares during the period. Finally, GM Advisory Group LLC lifted its holdings in Novo Nordisk A/S by 443.5% during the first quarter. GM Advisory Group LLC now owns 13,706 shares of the company's stock worth $952,000 after buying an additional 11,184 shares during the period. Hedge funds and other institutional investors own 11.54% of the company's stock.

Analysts Set New Price Targets

NVO has been the subject of a number of analyst reports. Wall Street Zen lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. HSBC lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 target price for the company. in a report on Thursday, July 31st. Hsbc Global Res downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 31st. BNP Paribas Exane raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price target on the stock in a research report on Wednesday, August 13th. Finally, Dbs Bank raised Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Friday. Three analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $81.00.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock traded down $1.05 during trading hours on Tuesday, hitting $55.29. 12,834,279 shares of the stock traded hands, compared to its average volume of 30,103,260. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The firm's 50 day moving average price is $61.78 and its 200-day moving average price is $68.90. The stock has a market capitalization of $246.86 billion, a price-to-earnings ratio of 15.19, a P/E/G ratio of 1.96 and a beta of 0.63. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.93 by $0.04. The business had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th will be given a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date of this dividend is Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 22.53%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.